Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07036185 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Shanghai Bao Pharmaceuticals Co., Ltd.
3 trials monitored
See all monitored trials
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
and 3 more diseases
This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.
Trial Details
NCT Number NCT07036185
Lead Sponsor Shanghai Bao Pharmaceuticals Co., Ltd.
Conditions
(from sponsor)		 Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Bile Duct Cancer, Head and Neck Squamous Cell Carcinoma
Related terms Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Squamous Cell Carcinoma of Head and Neck
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov